Literature DB >> 17644863

GH/IGF-I axis in anorexia nervosa.

L Gianotti1, F Lanfranco, J Ramunni, S Destefanis, E Ghigo, E Arvat.   

Abstract

Patients with anorexia nervosa (AN) may develop multiple endocrine abnormalities, including amenorrhea, hyperactivity of the hypothalamus-pituitary-adrenal axis, hypothyroidism and particular changes in the activity of the growth hormone (GH)/insulin-like growth factor I (IGF-I) axis. Exaggerated GH secretion and reduced IGF-I levels are usually found in AN, as well as in conditions of malnutrition and malabsorption, insulin-dependent diabetes mellitus, liver cirrhosis and catabolic states. In AN, GH hypersecretion at least partially reflects malnutrition-induced peripheral GH resistance, which leads to reduced IGF-I synthesis and release; this implies an impairment of the negative IGF-I feedback action on GH secretion. On the other hand, primary alterations in the neural control of GH secretion cannot be ruled out. The neuroendocrine alterations include enhanced somatotroph responsiveness to growth hormone releasing hormone (GHRH) and impaired GH response to most central nervous system-mediated stimuli. Particular resistance to cholinergic manipulation has also been demonstrated, thus suggesting a somewhat specific alteration in the somatostatin (SS)-mediated cholinergic influence on GH secretion. Moreover, paradoxical GH responses to glucose load, thyrotropin releasing hormone (TRH) and luteinizing hormone releasing hormone (LHRH) have also been reported. The effect of reduced leptin levels on GH hypersecretion in AN is still unclear, but ghrelin (the gastric hormone that is a natural ligand of the GH secretagogue receptor and strongly stimulates somatotroph secretion) is thought to play a major role. Regardless of the supposed central and peripheral alterations, it has to be emphasised that the activity of the GH/IGF-I axis in AN is generally restored by nutritional and stable weight gain. It therefore reflects an impaired nutritional state and cannot be considered a primary hallmark of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 17644863     DOI: 10.1007/bf03354435

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  110 in total

1.  The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations.

Authors:  J D Veldhuis; M L Carlson; M L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 2.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

3.  Responses of pituitary and adrenal medulla to insulin-induced hypoglycemia in patients with anorexia nervosa.

Authors:  K Nakagawa; M Matsubara; T Obara; M Kubo; K Akikawa
Journal:  Endocrinol Jpn       Date:  1985-10

4.  Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa.

Authors:  L Gianotti; S Fassino; G A Daga; F Lanfranco; C De Bacco; J Ramunni; E Arvat; M MacCario; E Ghigo
Journal:  Clin Endocrinol (Oxf)       Date:  2000-06       Impact factor: 3.478

5.  Paradoxical enhancement of pituitary growth hormone (GH) responsiveness to GH-releasing factor in the face of high somatostatin tone.

Authors:  G S Tannenbaum; J C Painson; A M Lengyel; P Brazeau
Journal:  Endocrinology       Date:  1989-03       Impact factor: 4.736

6.  Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.

Authors:  L Gianotti; M Rolla; E Arvat; D Belliti; M R Valetto; M Ferdeghini; E Ghigo; E E Müller
Journal:  Biol Psychiatry       Date:  1999-02-01       Impact factor: 13.382

Review 7.  Human growth hormone.

Authors:  J S Strobl; M J Thomas
Journal:  Pharmacol Rev       Date:  1994-03       Impact factor: 25.468

Review 8.  Physiology of growth hormone secretion and action.

Authors:  F F Casanueva
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

9.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

10.  Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa.

Authors:  E Ghigo; E Arvat; L Gianotti; M Nicolosi; M R Valetto; S Avagnina; D Bellitti; M Rolla; E E Müller; F Camanni
Journal:  Biol Psychiatry       Date:  1994-11-15       Impact factor: 13.382

View more
  10 in total

1.  Psychopathology in underweight and weight-recovered females with anorexia nervosa.

Authors:  N Schneider; H Salbach-Andrae; J V Merle; J Hein; E Pfeiffer; U Lehmkuhl; S Ehrlich
Journal:  Eat Weight Disord       Date:  2009-12       Impact factor: 4.652

Review 2.  Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research.

Authors:  Anna Csiszar; Priya Balasubramanian; Stefano Tarantini; Andriy Yabluchanskiy; Xin A Zhang; Zsolt Springo; Doris Benbrook; William E Sonntag; Zoltan Ungvari
Journal:  Geroscience       Date:  2019-04-29       Impact factor: 7.713

3.  A Human Variant of Glucose-Regulated Protein 94 That Inefficiently Supports IGF Production.

Authors:  Michal Marzec; Colin P Hawkes; Davide Eletto; Sarah Boyle; Ron Rosenfeld; Vivian Hwa; Jan M Wit; Hermine A van Duyvenvoorde; Wilma Oostdijk; Monique Losekoot; Oluf Pedersen; Bu Beng Yeap; Leon Flicker; Nir Barzilai; Gil Atzmon; Adda Grimberg; Yair Argon
Journal:  Endocrinology       Date:  2016-03-16       Impact factor: 4.736

4.  Growth hormone deficiency and cerebral palsy.

Authors:  Jesús Devesa; Nerea Casteleiro; Cristina Rodicio; Natalia López; Pedro Reimunde
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

Review 5.  Systemic illness.

Authors:  Marta Bondanelli; Maria Chiara Zatelli; Maria Rosaria Ambrosio; Ettore C degli Uberti
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

6.  Glial and neuronal damage markers in patients with anorexia nervosa.

Authors:  Stefan Ehrlich; Roland Burghardt; Deike Weiss; Harriet Salbach-Andrae; Eugenia Maria Craciun; Klaus Goldhahn; Burghard F Klapp; Ulrike Lehmkuhl
Journal:  J Neural Transm (Vienna)       Date:  2008-03-04       Impact factor: 3.575

7.  Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa.

Authors:  S Fassino; F Lanfranco; G Abbate Daga; V Mondelli; S Destefanis; G G Rovera; F Camanni; E Ghigo; E Arvat; L Gianotti
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

Review 8.  Nutrition and pubertal development.

Authors:  Ashraf Soliman; Vincenzo De Sanctis; Rania Elalaily
Journal:  Indian J Endocrinol Metab       Date:  2014-11

9.  Apelin-13 and Asprosin in Adolescents with Anorexia Nervosa and Their Association with Psychometric and Metabolic Variables.

Authors:  Katarzyna Jowik; Monika Dmitrzak-Węglarz; Natalia Pytlińska; Anna Jasińska-Mikołajczyk; Agnieszka Słopień; Marta Tyszkiewicz-Nwafor
Journal:  Nutrients       Date:  2022-09-28       Impact factor: 6.706

10.  Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance.

Authors:  A Rickenlund; M Thorén; A Nybacka; J Frystyk; A Lindén Hirschberg
Journal:  Hum Reprod       Date:  2009-10-19       Impact factor: 6.918

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.